Medtronic Announces Departure of Chief Financial Officer Karen Parkhill

DUBLIN, June 26, 2024 /PRNewswire/ — Medtronic plc (NYSE: TDM), a global leader in healthcare technology, today announced that Karen Parkhill will step down from her role as executive vice president and chief financial officer to accept the role of chief financial officer at HP Inc.

“On behalf of our employees, our executive committee and our board of directors, I want to thank Karen for her leadership over the past eight years. I am personally grateful to Karen for her support during my transition to CEO, navigating the pandemic and delivering a new operating model for the company. We wish her all the best as she takes on the next chapter of her career,” said Geoff Martha, president and CEO of Medtronic. “Companywide, we are building momentum with our innovation-driven growth strategy, and we remain focused and committed to delivering on our short- and long-term financial objectives.”

“It has been a pleasure to serve Medtronic and our mission for the past eight years,” said Parkhill. “I am grateful to have had the opportunity to lead Medtronic’s excellent finance team and know they will continue to deliver on our commitments. I remain excited about Medtronic’s plans for the future and, most importantly, the tremendous impact Medtronic’s technologies will have on the lives of patients around the world.”

The company is evaluating internal and external candidates for succession. Parkhill will continue to serve as CFO until her departure on August 2, and Gary Corona, senior vice president of Global Financial Planning and Analysis, will serve as interim CFO upon her departure.

Additionally, the company also reaffirmed guidance for the first quarter and full fiscal year 2025, as previously disclosed in its May 23, 2024 press release and earnings webcast.

About Medtronic
Bold thinking. Bolder action. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly tackles humanity’s most challenging health problems by finding and finding solutions. Our mission — to alleviate pain, restore health and extend life — unites a global team of more than 95,000 passionate people in over 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems and more. Fueled by our diverse expertise, insatiable curiosity and desire to help everyone in need, we deliver breakthrough technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we power insight-driven care, people-first experiences and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information about Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacture, marketing and sale of medical products, government regulation, geopolitical conflicts, general economic conditions and other risks and uncertainties described in the company’s periodic reports filed with the U.S. Securities and Exchange Commission, including the company’s most recent Annual Report on Form 10-K. Medtronic undertakes no obligation to update its forward-looking statements, including to reflect future events or circumstances.

SOURCE Medtronic plc

Source